• Je něco špatně v tomto záznamu ?

Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer

I. Kolarova, L. Dusek, A. Ryska, K. Odrazka, M. Dolezel, J. Vanasek, B. Melichar, J. Petera, T. Buchler, M. Vosmik, K. Petrakova, P. Terarova, Z. Vilasova, J. Jarkovsky

. 2020 ; 34 (6) : 3441-3449. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019893

BACKGROUND/AIM: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. PATIENTS AND METHODS: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. RESULTS: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. CONCLUSION: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019893
003      
CZ-PrNML
005      
20210830101513.0
007      
ta
008      
210728s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12183 $2 doi
035    __
$a (PubMed)33144452
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kolarova, Iveta $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic
245    10
$a Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer / $c I. Kolarova, L. Dusek, A. Ryska, K. Odrazka, M. Dolezel, J. Vanasek, B. Melichar, J. Petera, T. Buchler, M. Vosmik, K. Petrakova, P. Terarova, Z. Vilasova, J. Jarkovsky
520    9_
$a BACKGROUND/AIM: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. PATIENTS AND METHODS: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. RESULTS: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. CONCLUSION: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    12
$a nádory prsu $x farmakoterapie $x genetika $7 D001943
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hormony $7 D006728
650    _2
$a lidé $7 D006801
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a prognóza $7 D011379
650    _2
$a receptor erbB-2 $x genetika $7 D018719
650    _2
$a retrospektivní studie $7 D012189
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Odrazka, Karek $u Oncology Centre, Multiscan, Pardubice, Czech Republic $u Department of Clinical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic $u Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Postgraduate Medical Education, Prague, Czech Republic
700    1_
$a Dolezel, Martin $u Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Oncology, Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Vanasek, Jaroslav $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic $u Oncology Centre, Multiscan, Pardubice, Czech Republic $u Department of Clinical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Oncology, Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Petera, Jiri $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Vosmik, Milan $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Petrakova, Katarina $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Terarova, Petra $u Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Oncology, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Vilasova, Zdena $u Oncology Centre, Multiscan, Pardubice, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic jarkovsky@iba.muni.cz
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 34, č. 6 (2020), s. 3441-3449
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33144452 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101513 $b ABA008
999    __
$a ok $b bmc $g 1690654 $s 1140339
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 6 $d 3441-3449 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace